Home > Resources > Whitepapers > Connecting the Dots in Specialty Pharmacy Data

Connecting the Dots in Specialty Pharmacy Data

June 22, 2016

The rapidly expanding specialty pharmacy market has created unique challenges for pharmaceutical manufacturers looking to obtain dispensing, adherence, and switching data for specialty drugs. Access to timely, anonymized, longitudinal patient data forms the foundation of brand analytics within pharmaceutical manufacturers. While there are numerous syndicated sources for retail pharmacy data for traditional drugs, a comparable source for specialty drug data does not exist. Strong growth within the fragmented specialty pharmacy industry means that specialty drug data are now spread across a large number of pharmacies that include independent pharmacies, retailers/chains, hospitals, health plans, and pharmacy benefits managers (PBMs).

I'm For Real

Enter your details once to access all our information and resources

 

Spotlight

Nano Bio Technology Fardanegar (NBTF)

Nano Bio Technology Fardanegar Cooperative Company (NBTF) is a knowledge-based company active in the fields of biotechnology, nano biotechnology, and in particular the production of nano particles and pharmaceutical nano carriers. The Company Started its activities on 2014 in the field of new sciences, especially in the field of Nano Biotechnology.

OTHER WHITEPAPERS
news image

Best Practices for RIM Business Process Automation

whitePaper | December 29, 2022

Regulatory teams at life science companies are finding that effective regulatory information management (RIM) has become critical to their operations.

Read More
news image

NEXTGEN PHARMA TAKES ‘SMART’ STRIDES WITH INTERNET OF THINGS

whitePaper | December 20, 2022

Digitization of processes and data across the value chain along with the emergence of Internet of Things (IoT) has transformed the Pharma industry.

Read More
news image

Investing in Next-Generation Tokenization and Real-World Data to Unlock a More Precise and Complete Patient Journey

whitePaper | November 18, 2022

To realize the full potential of RWD, we must put the patient at the center and truly understand each patient’s unique circumstances over time. It’s certainly a tall order when the data we need is scattered across siloed systems and guarded by applicable and necessary patient privacy regulations.

Read More
news image

Global Use of Medicines 2023

whitePaper | January 18, 2023

Reaching a post-pandemic era is an alluring prospect for almost everyone around the world after the disruptions of the past three years.

Read More
news image

Optimizing the Path from Pre-Clinical to Clinical Development

whitePaper | December 22, 2022

According to research, post-pandemic R&D growth is healthy in the pharma industry with the number of drugs in the R&D pipeline now exceeding 20,000 in 2022—which represents an expansion rate of 8.22% from 2021 (1).

Read More
news image

Empowering MSLs to be the kings of Pharma’s New Frontier

whitePaper | December 12, 2022

To improve outcomes for cancer patients and take advantage of the groundbreaking scientific and technological progress made in oncology prevention, diagnosis, therapy

Read More

Best Practices for RIM Business Process Automation

whitePaper | December 29, 2022

Regulatory teams at life science companies are finding that effective regulatory information management (RIM) has become critical to their operations.

Read More

NEXTGEN PHARMA TAKES ‘SMART’ STRIDES WITH INTERNET OF THINGS

whitePaper | December 20, 2022

Digitization of processes and data across the value chain along with the emergence of Internet of Things (IoT) has transformed the Pharma industry.

Read More

Investing in Next-Generation Tokenization and Real-World Data to Unlock a More Precise and Complete Patient Journey

whitePaper | November 18, 2022

To realize the full potential of RWD, we must put the patient at the center and truly understand each patient’s unique circumstances over time. It’s certainly a tall order when the data we need is scattered across siloed systems and guarded by applicable and necessary patient privacy regulations.

Read More

Global Use of Medicines 2023

whitePaper | January 18, 2023

Reaching a post-pandemic era is an alluring prospect for almost everyone around the world after the disruptions of the past three years.

Read More

Optimizing the Path from Pre-Clinical to Clinical Development

whitePaper | December 22, 2022

According to research, post-pandemic R&D growth is healthy in the pharma industry with the number of drugs in the R&D pipeline now exceeding 20,000 in 2022—which represents an expansion rate of 8.22% from 2021 (1).

Read More

Empowering MSLs to be the kings of Pharma’s New Frontier

whitePaper | December 12, 2022

To improve outcomes for cancer patients and take
advantage of the groundbreaking scientific and
technological progress made in oncology prevention,
diagnosis, therapy

Read More
More Whitepapers

Spotlight

Nano Bio Technology Fardanegar (NBTF)

Nano Bio Technology Fardanegar Cooperative Company (NBTF) is a knowledge-based company active in the fields of biotechnology, nano biotechnology, and in particular the production of nano particles and pharmaceutical nano carriers. The Company Started its activities on 2014 in the field of new sciences, especially in the field of Nano Biotechnology.

Events

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference

Pharma 2024

Conference

Pharma 2024

Conference